Overall Score

Political

No material political/regulatory developments were provided this month.

IVVD remains a small-cap biotech with limited direct political exposure beyond standard healthcare reimbursement and FDA oversight.

Economic

The company’s liquidity remains strong with a current ratio of 5.87x and cash ratio of 5.16x, supporting near-term resilience.

Valuation remains mixed: EV/Sales is 2.27x, but profitability and cash-flow metrics are still negative, limiting economic quality.

Social

No new social or demand-shift news was provided this month.

As a biotech company, adoption depends on clinical and physician/patient acceptance, but no fresh evidence changed that view.

Technological

Gross margin remains very high at 91.35%, suggesting a potentially attractive product economics profile if commercialization scales.

R&D intensity remains elevated at 1.34x revenue, indicating continued dependence on pipeline execution and product development.

Legal

No new litigation, compliance, or IP developments were provided this month.

The company still faces typical biotech legal risk around regulatory approval, intellectual property, and commercialization execution.

Environmental

No material environmental developments were provided this month.

Environmental exposure appears limited relative to industrial sectors, with no fresh evidence of change.